Overexpression of METTL14 inhibits HCC malignant progression by upregulating m6A expression levels of genes critical for prognosis in HCC patients, such as cysteine sulfite decarboxylase, glutamate-oxaloacetate transaminase 2, and cytokine signaling inhibitor 2 (Li et al., 2020). Here, METTL14 is linked to hepatocellular carcinoma.